University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 14 of 23

COMPLETED Phase 2

FARE Peanut SLIT and Early Tolerance Induction

NCT02304991

COMPLETED

ARC in Hemorrhagic Stroke

NCT02386202

COMPLETED NA

Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis

NCT02312713

COMPLETED NA

Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach

NCT02309099

COMPLETED NA

PPV to Guide Fluid Management in the PICU

NCT02308371

TERMINATED

Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients

NCT02215148

COMPLETED NA

Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy

NCT02106910

COMPLETED NA

Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.

NCT02218541

COMPLETED NA

Study of an Emergency Department-based Intervention to Reduce Alcohol Misuse in Older Adults

NCT02236494

COMPLETED

To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma

NCT02671643

COMPLETED NA

Cochlear Implantation in Cases of Single-Sided Deafness

NCT02203305

COMPLETED

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

NCT02218320

COMPLETED NA

Impact of Graphic Cigarette Warnings

NCT02247908

COMPLETED NA

Uniting Couples In the Treatment of Eating Disorders (UNITE)

NCT02419326

COMPLETED Phase 4

LNG-IUS at 2 Weeks Postpartum

NCT02121067

COMPLETED Phase 1

Brain Imaging of Intranasal Oxytocin Treatment in Autism

NCT01945957

COMPLETED NA

Heart Healthy Lenoir: Return of Results Study

NCT02208180

COMPLETED NA

Home Administration of FluMist by Parents/Caregivers

NCT01938170

COMPLETED Phase 1

Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?

NCT02226484

COMPLETED NA

Sex and Female Empowerment

NCT02197715

COMPLETED

Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis

NCT02228915

COMPLETED NA

Mushroom Blend on Oxygen Kinetics

NCT02075892

COMPLETED Early Phase 1

Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers

NCT02183753

COMPLETED NA

Nutrition for Migraine Prevention

NCT02012790

COMPLETED NA

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

NCT02167919

COMPLETED NA

Cohort Study of Risk Reducing Salpingectomy

NCT02165709

COMPLETED

Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers

NCT02019745

COMPLETED NA

A Pilot Study Evaluating Go NAP SACC's Web-based Nutrition Tool for Child Care

NCT02889198

COMPLETED

Determining Relationships Among Maternity Stress & Sleep

NCT02133963

COMPLETED NA

Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5

NCT02098902

COMPLETED NA

FL3X Study: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes (FL3X)

NCT01286350

TERMINATED NA

Feasibility of Heart Rate Variability Biofeedback With In-patient Pregnant Women

NCT02119936

COMPLETED Phase 3

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

NCT02068846

COMPLETED Phase 1

Choline Dehydrogenase and Sperm Function: Effects of Betaine

NCT02122211

COMPLETED

Fatty Acids and Executive Function Development in 7-12 Year Olds

NCT02199808

COMPLETED NA

Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients

NCT03057236

COMPLETED

Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management

NCT02075905

COMPLETED

Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech

NCT02094014

COMPLETED Phase 1

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

NCT02039323

COMPLETED Phase 2

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668

COMPLETED NA

Effect of Compression Garments on Exercise Performance Following Acute High Intensity Exercise

NCT02076334

COMPLETED Phase 1

Phase I Study of Nicotinamide for Early Onset Preeclampsia

NCT02213094

COMPLETED NA

Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

NCT01963676

COMPLETED NA

Improving Colon Cancer Screening for Diverse Populations

NCT02054598

COMPLETED NA

Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes

NCT02033499

COMPLETED Phase 2

Efficacy and Safety of High Dose Baclofen for Alcohol Dependence

NCT01980706

COMPLETED NA

Improving Diabetes Outcomes for Persons With Severe Mental Illness

NCT02053714

COMPLETED

Oxytocin Levels in Typically Developing Boys

NCT02006381

COMPLETED

Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall

NCT02105896

COMPLETED

A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)

NCT01998269

← Previous Page 14 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.